Cargando…

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?

Detalles Bibliográficos
Autores principales:	Schlam, Ilana, Tolaney, Sara M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8092338/ https://www.ncbi.nlm.nih.gov/pubmed/33953840 http://dx.doi.org/10.18632/oncotarget.27904

Ejemplares similares

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
por: Mittal, Abhenil, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

How I treat HER2-low advanced breast cancer
por: Schlam, Ilana, et al.
Publicado: (2023)

Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases
por: Kubeczko, Marcin, et al.
Publicado: (2023)

CDK4/6 inhibition in breast cancer: current practice and future directions
por: Pernas, Sonia, et al.
Publicado: (2018)

The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
por: Grinshpun, Albert, et al.
Publicado: (2023)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Artificial intelligence as an adjunct tool for breast oncologists – are we there yet?
por: Schlam, I., et al.
Publicado: (2023)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
por: Akhade, Amol, et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
por: George, Mridula A., et al.
Publicado: (2021)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
por: Mohammed, Amrallah A., et al.
Publicado: (2019)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
por: Piezzo, Michela, et al.
Publicado: (2020)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
por: Rossi, Lorenzo, et al.
Publicado: (2018)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Scheidemann, Erin R., et al.
Publicado: (2021)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer()
por: Loibl, Sibylle, et al.
Publicado: (2021)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
por: Xu, Hanxiao, et al.
Publicado: (2017)

The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
por: Gomes, Inês, et al.
Publicado: (2023)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
por: Pandey, Kamal, et al.
Publicado: (2019)

Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
por: Main, Sasha C., et al.
Publicado: (2022)

Cellular senescence in the response of HR(+) breast cancer to radiotherapy and CDK4/6 inhibitors
por: Klapp, Vanessa, et al.
Publicado: (2023)

Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer
por: Zhu, Xiang, et al.
Publicado: (2023)

Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

CDK4/6 inhibition: the late harvest cycle begins
por: Goel, Shom, et al.
Publicado: (2016)

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vgpv9lja1lkv9ns3r2vjpg2840